Fig. 4
Downregulation of TAB182 causes cell resistance to olaparib or cisplatin treatment. A-B Colony formation assay in shTAB182 #1, shTAB182 #2, and shNC MDA-MB-231 cells (A) and BT549 cells (B) after olaparib or DMSO treatment for seven days at the indicated concentrations. * P < 0.05, ** P < 0.01, shTAB182 #1 or #2 compared to the corresponding shNC after treatment with each concentration of olaparib, as determined by Student’s t test. The measurement of shNC-0 μM was used for normalization. The data are shown as the means with SD (n = 3). C-D Colony formation assay of shTAB182 #1, shTAB182 #2, and shNC MDA-MB-231 cells (C) and BT549 cells (D) after cisplatin or ddH2O treatment for seven days at the indicated concentrations. * P < 0.05, ** P < 0.01 and *** P < 0.001, shTAB182 #1 or #2 compared to the corresponding shNC after treatment with each concentration of cisplatin as determined by Student’s t test. The measurement of shNC-0 μM was used for normalization. The data are shown as the means with SD (n = 3). E–F CCK-8 assay using MDA-MB-231 cells overexpressing TAB182 (TAB182 O. E) or control cells (Vec) treated with 10 μM olaparib (Ola, E) or 1.25 μM cisplatin (Cis, F). DMSO or ddH2O was used as the control, and OD values were measured on Day 0, Day 1, Day 2, and Day 3 after treatment. The absorbance measured on Day 0 was used for normalization. The data are shown as the means with SD (n = 3). * P < 0.05, *** P < 0.001, compared with Vec + DMSO/ddH2O; ### P < 0.001, TAB182 O. E + Ola/Cis vs. Vec + Ola/Cis, by Student’s t test (n = 3)